Ameron International Announces Plans to Build New Steel Pole Plant in Oklahoma

Ameron International Corporation (NYSE: AMN) today announced plans to construct a new steel pole plant in Tulsa, Oklahoma.

The capital investment for the 75,000-square-foot facility is expected to total approximately $35 million, and the plant should be operational within two years. The facility will include a proprietary manufacturing process and when fully operational the facility would have an annual sales capacity of up to $75 million. The manufacturing capabilities provided by this investment will allow the business to effectively compete in a broad range of product applications utilized in the national transportation market.

This strategic initiative focuses on the national transportation infrastructure market for applications, such as highway lighting, traffic signal control structures, light rail, high mast and smart grid structures, and highway signage. These are large national markets that generally benefit from federal and state funding and that are forecasted to experience long-term, steady growth to support the necessary expansion and upgrade of the U.S. transportation system. The broad steel pole product line would complement the Company’s market-leading line of decorative concrete lighting poles used in commercial and residential markets. In addition, it is expected that offering a full steel pole and concrete pole line would provide synergies throughout the distribution network.

James S. Marlen, Ameron’s Chairman, President and Chief Executive Officer, stated, “This investment represents a significant strategic growth opportunity in a market with which we have experience. With the new plant, we will have a cost-efficient, state-of-the-art manufacturing process and the capacity to grow the business.”

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.